Giant-cell arteritis

Current Opinion in Ophthalmology

Volumn 19, Issue 6, 2008, Pages 454-460

  Hall, Jennifer K ^a  

^a WILLS EYE HOSPITAL   (United States)

Author keywords

Aspirin; Giant cell arteritis; Interleukin 6; Methotrexate; Methylprednisolone; Temporal artery biopsy

Indexed keywords

ACETYLSALICYLIC ACID; ATLIZUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; ETANERCEPT; FIBRINOGEN; FLUORODEOXYGLUCOSE F 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; STEROID;

BLEEDING; COLOR ULTRASOUND FLOWMETRY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; GIANT CELL ARTERITIS; HUMAN; LOW DRUG DOSE; MAGNETIC RESONANCE ANGIOGRAPHY; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOCYTE COUNT; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT;

ASPIRIN; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FIBRINOGEN; FLUORODEOXYGLUCOSE F18; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-6; MAGNETIC RESONANCE ANGIOGRAPHY; METHOTREXATE; PLATELET COUNT; RADIOPHARMACEUTICALS; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 56249114523     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e328310da01     Document Type: Review

References (50)

1. Boyev L, Miller N, Green W. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol 1999; 128:211-215.
2. Hall J, Volpe N, Galetta S, et al. The role of unilateral temporal artery biopsy. Ophthalmology 2003; 110:543-548.
3. Danesh-Meyer H, Savino PJ, Eagle RJ Jr, et al. Low diagnostic yield with second biopsies in suspected giant cell arteritis. J Neuroophthalmol 2000; 20:213-215.
4. Niederkohr RD, Levin LA. A Bayesian analysis of the true sensitivity of a temporal artery biopsy. Invest Ophthalmol Vis Sci 2007; 48:675-680.
5. Bley TA, Weiben O, Uhl M, et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum 2005; 52:2470-2477.
6. Karahaliou M, Vaiopoulos G, Papaspyrou S, et al. Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res Ther 2006; 8:R116.
7. Luneau K, Zhou L, Biousse V, et al. Immunohistochemical assesment of giant cell arteritis (GCA): implications for clinical diagnosis and disease activity. In: 34th annual meeting of the North American Neuro-Ophthalmology Society; 2008; Orlando, Florida. Enhanced diagnostic capability of TAB specimens is desirable. No benefit from immunohistochemical staining of CD3 or CD68 was suggested by preliminary results of this study. However, this is an important avenue of inquiry that is advanced by this finding.
8. Slobodin G, Lurie M, Bejar J, et al. Biopsy-negative giant cell arteritis: does anti-CD83 immunohistochemistry advance the diagnosis? Eur J Intern Med 2007; 18:405-408. This study did not demonstrate added benefit from immunohistochemical staining of CD83 in the analysis of TAB specimens. Although a negative finding, this information advances efforts to increase the diagnostic accuracy of TAB.
9. Hayreh SS, Podhajsky PA, Raman R, et al. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997; 123:285-296.
10. Parikh M, Miller NR, Lee AG, et al. Prevalence of a normal CRP with and elevated ESR in biopsy-proven giant cell arteritis. Ophthalmology 2006; 113:1842-1845.
11. Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore) 2005; 84:277-290.
12. Costello F, Zimmerman MB, Podhajsky PA, et al. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from nonarteritic anterior ischemic optic neuropathy. Eur J Ophthalmol 2004; 14:245-257.
13. Foroozan R, Danesh-Meyer H, Savino PJ, et al. Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology 2002; 109:1267-1271.
14. Niederkohr R, Levin LA. Management of the patient with suspected temporal arteritis. Ophthalmology 2005; 112:744-756.
15. Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000; 43:1041-1048.
16. Weyand C, Hicok K, Hunder G, et al. Tissue cylokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994; 121:484-491.
17. Holdstock G, Mitchell J. Erythrocyte sedimentation rate before and after invitro defibrination: a rapid and simple method for increasing its specificity. Lancet 1977; 2:1314-1316.
18. Karassa FB, Matsagas MI, Schmidt WA, et al. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med 2005; 142:359-369.
19. Salvarani C, Silingardi M, Ghirarduzzi A, et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? Ann Intern Med 2002; 137:232-238.
20. Schmidt WA, Kraft HE, Vorpahl K, et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337:1336-1342.
21. Bley T, Wieben O, Uhl M, et al. Integrated head-thoracic vascular MRI at 3T: assessment of cranial, cervical and thoracic involvement of giant cell arteritis. MAGMA 2005; 18:193-200.
22. Bley TA, Uhl M, Carew J, et al. Diagnostic value of high-resolution MR imaging in giant cell arteritis. Am J Neuroradiol 2007; 28:1722-1727.
23. Bley TA, Markl M, Schelp M, et al. Mural inflammatory hyperenhancement in MRI of giant cell (temporal) arteritis resolves under corticosteroid treatment. Rheumatology (Oxford) 2008; 47:65-67. This small study of 17 GCA patients (ACR criteria) supports the ability of high-resolution MRI to detect GCA-associated vascular changes, and suggests a possible role for MRI in monitoring disease course.
24. Bleeker-Rovers C, Bredie S, van der Meer J, et al. F-18- fluorodeoxyglucose positron emission tomography in diagnosis and follow-up of patients with different types of vasculitis. Neth J Med 2003; 61:323-329.
25. Brodmann M, Lipp R, Passath A, et al. The role of 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of giant cell arteritis of the temporal arteries. Rheumatology 2004; 43:241-242.
26. Blockmans D, Stroobants S, Maes A, et al. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 2000; 108:246-249.
27. Scheel A, Meiler J, Vosshenrich R, et al. Diagnosis and follow up of aortitis in the elderly. Ann Rheum Dis 2004; 63:1507-1510.
28. De Winter F, Petrovic M, Van de Wiele C, et al. Imaging of giant cell arteritis: evidence of splenic involvement using FDG positron emission tomography. Clin Nucl Med 2000; 25:633-634.
29. Birkhead N, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids. JAMA 1957; 163:821-827.
30. Liu GT, Glaser JS, Schatz NJ. Visual morbidity in giant cell arteritis: clinical characteristics and prognosis for vision. Ophthalmology 1994; 101:1779-1785.
31. Chan C, Paine M, O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol 2001; 85:1061-1064.
32. Hayreh S, Zimmerman B, Kardon R. Visual improvement with corticosteroid therapy in giant cell arteritis: report of a large study and review of literature. Acta Ophthalmol Scand 2002; 80:355-367.
33. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis. Arthritis Rheum 1998; 41:1497-1504.
34. Gordon L, Levin L. Visual loss in giant cell arteritis. JAMA 1998; 280:385-386.
35. Hall E. Neuroprotective actions of glucocorticoid and nonglucocorticoid steroids in acute neuronal injury. Cell Mol Neurobiol 1993; 13:415-432.
36. Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006; 54:3310-3318. This double-blind placebo-controlled randomized trial of 27 biopsy-proven patients yielded convincing evidence that induction of therapy with intravenous steroids is steroid-sparing.
37. Spiera R, Mitnick H, Kupersmith M, et al. A prospective, double-bind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis. Clin Exp Rheumatol 2001; 19:495-501.
38. Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46:1309-1318.
39. Jover JA, Hernandez-Garcia C, Morado I, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. Ann Intern Med 2001; 134:106-114.
40. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007; 56:2789-2797. Previous studies on the efficacy of adjunctive methotrexate have yielded conflicting results. The scope of this meta-analysis of 161 patients from three placebo-controlled trials lends support to methotrexate as an effective steroid-sparing agent.
41. Cantini F, Niccoli L, Salvarani C, et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001; 44: 2933-2935.
42. Airo PAC, Vianelli M, et al. Antitumor necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology 2002; 41:347-349.
43. Huffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146:621-630. In this randomized, double-blind, placebo-controlled study of 44 GCA patients (83% biopsy-proven), no steroid-sparing effect was seen with infliximab. Although the study had limitations, it diminishes promise for infliximab as an effective steroid-sparing agent.
44. Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67:625-630. In this small randomized, double-blind, placebo-controlled study of 17 biopsy-proven GCA patients, a significantly lower cumulative steroid dose was observed at 1 year in patients receiving adjunctive etanercept versus placebo. This did not translate into diminished steroid-related side effects.
45. Salvarani C, Hunder GG. Tumor necrosis factor blocking agents in polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 2008; 148:167-168; author reply 8.
46. Salvarani C, Pipitone N, Boiardi L, et al. Do we need treatment with tumour necrosis factor blockers for giant cell arteritis? Ann Rheum Dis 2008; 67:577-579.
47. Weyand CM, Kaiser M, Yang H, et al. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002; 46:457-466.
48. Nesber G, Berkun Y, Mates M, et al. Low dose aspirin and prevention of cranial ischemis compications in giant cell arteritis. Arthritis Rheum 2004; 50:1332-1337.
49. Narvaez J, Bemad B, Nolla JM, et al. Statin therapy does not seem to benefit giant cell arteritis. Semin Arthritis Rheum 2007; 36:322-327. This study indicates an unlikely role for statins in GCA treatment.
50. Lozano E, Segarra M, Garcia-Martinez A, et al. Imatinib mesylate inhibits in vitro and ex vivo biologic responses related to vascular occlusion in giant-cell arteritis. Ann Rheum Dis [Accessed 21 June 2007]. This study provides basis for further investigation of a potential therapeutic agent, imatinib-mesylate.